Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

2.9K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.9K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.7K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.7K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.4K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

3.3K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.3K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

4.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Construction and Practice of the "Leading Goose Navigation and Four-Dimensional Synergy" Model for Cultivating Top Innovative Talents in Forensic Medicine].

Fa yi xue za zhi·2026
Same author

Differential thermal stability of mRNA, miRNA and lncRNA in purified human tissue-derived RNA extracts: a proof-of-principle study with forensic implications.

Legal medicine (Tokyo, Japan)·2026
Same author

A Preliminary Study of Pig Carcass Decomposition and Necrophagous Fly Community Dynamics on Hainan Island, China.

Insects·2026
Same author

Estimating time of day from fingertip blood samples using RNA molecules with diurnal oscillating expression: a proof-of-principle study.

International journal of legal medicine·2026
Same author

ML-Powered MultiFluid-mRNAplex31: A Self-Developed Panel for Precise Tracing of Five Body Fluids.

Genomics, proteomics & bioinformatics·2026
Same author

An in silico evaluation of tri-allelic SNPs from 1kGP Phase IV data for distant kinship identification and mixture analysis.

Forensic science international. Genetics·2026

Related Experiment Video

Updated: Mar 9, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.9K

Parthenolide inhibits methamphetamine-induced depressive-like behavior by targeting ADORA2A.

Rongji Hui1, Tao Feng2, Congcong Hou3

  • 1College of Forensic Medicine, Hebei Medical University, Hebei Key Laboratory of Forensic Medicine, Collaborative Innovation Center of Forensic Medical Molecular Identification, Hebei Province, Shijiazhuang 050017, China; Hebei Medical University Basic Medicine Postdoctoral Research Station, Hebei Province, Shijiazhuang 050017, China.

Phytomedicine : International Journal of Phytotherapy and Phytopharmacology
|March 8, 2026
PubMed
Summary

Parthenolide effectively treats methamphetamine-induced depression-like behaviors by targeting ADORA2A signaling in the medial prefrontal cortex (mPFC). This natural compound shows promise for substance-induced mood disorders.

Keywords:
ADORA2ADepressionMetabolomicsMethamphetamineNetwork pharmacology

More Related Videos

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.6K
Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
07:30

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry

Published on: November 21, 2012

14.4K

Related Experiment Videos

Last Updated: Mar 9, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.9K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.6K
Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
07:30

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry

Published on: November 21, 2012

14.4K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Methamphetamine (METH) abuse causes persistent depressive behaviors with limited treatment options.
  • Parthenolide, a natural compound, has neuroprotective and anti-inflammatory effects but its role in METH-induced depression is unstudied.

Purpose of the Study:

  • To investigate parthenolide's efficacy in alleviating METH-induced depressive behaviors.
  • To identify key brain regions and molecular targets involved in parthenolide's therapeutic effects.

Main Methods:

  • Mice received METH and parthenolide treatment, followed by behavioral, histological, and neural activity assessments.
  • Metabolomics and network pharmacology predicted targets, validated through molecular docking, simulations, and assays.
  • Pharmacological modulation confirmed the role of identified targets.

Main Results:

  • Parthenolide significantly ameliorated METH-induced depressive-like behaviors in mice.
  • The medial prefrontal cortex (mPFC) was identified as a key region affected by METH, with parthenolide reducing neuronal damage.
  • ADORA2A was identified as a crucial molecular target, validated by pharmacological experiments.

Conclusions:

  • Parthenolide alleviates METH-induced depression by modulating ADORA2A signaling within the mPFC.
  • This study provides mechanistic insights into parthenolide's antidepressant-like effects.
  • Parthenolide is a potential therapeutic candidate for substance-induced mood disorders.